CO5700801A2 - Tratamiento del transtorno por deficit de atencion con hiper actividad - Google Patents
Tratamiento del transtorno por deficit de atencion con hiper actividadInfo
- Publication number
- CO5700801A2 CO5700801A2 CO05056569A CO05056569A CO5700801A2 CO 5700801 A2 CO5700801 A2 CO 5700801A2 CO 05056569 A CO05056569 A CO 05056569A CO 05056569 A CO05056569 A CO 05056569A CO 5700801 A2 CO5700801 A2 CO 5700801A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- substituted
- effective amount
- haloalkyl
- cycloalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Developing Agents For Electrophotography (AREA)
- Liquid Crystal Substances (AREA)
Abstract
1.- Una composición que comprende una cantidad eficaz de un agonista completo de nAChR a7 y una cantidad eficaz de un inhibidor de la recaptación de monoamina, una cantidad eficaz de un psicoestimulante, o una cantidad eficaz de un inhibidor de la recaptación de monoamina y una cantidad eficaz de un psicoestimulante.2.- La composición de la reivindicación 1, en la que el agonista es un compuesto de Fórmula I: Azabiciclo-N(R1)-C(=X)-W Fórmula I en la que azabiciclo es donde X es O o S;R0 es H, alquilo inferior, alquilo inferior sustituido o haloalquilo inferior;Cada R1 es H, alquilo, cicloalquilo, haloalquilo, fenilo sustituido o naftilo sustituido;Cada R2 es independientemente F, CI, Br, I, alquilo, alquilo sustituido, haloalquilo, cicloalquilo, arilo, o R2 está ausente con la condición de que k1-2, k1-6, k2, k5, k6 o k7 es 0;k1-2 es 0 ó 1;k1-6 es 0 ó 1, con la condición de que la suma de k1-2 y k1-6 sea uno;k2 es 0 ó 1;k5 es 0, 1, ó 2;k6 es 0, 1 ó 2;k7 es 0 ó 1;R2-3 es H, F, CI, Br, I, alquilo, haloalquilo, alquilo sustituido, cicloalquilo, o arilo;Cada R3 es independientemente H, alquilo o alquilo sustituido;R4 es H, alquilo, un grupo protector amino o un grupo alquilo que tiene 1-3 sustituyentes seleccionados entre F, CI, Br, I, -OH, -CN, -NH2, -NH(alquilo) o -N(alquilo)2; ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43258602P | 2002-12-11 | 2002-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5700801A2 true CO5700801A2 (es) | 2006-11-30 |
Family
ID=32507968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05056569A CO5700801A2 (es) | 2002-12-11 | 2005-06-10 | Tratamiento del transtorno por deficit de atencion con hiper actividad |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20050107425A1 (es) |
| EP (1) | EP1572300A1 (es) |
| JP (1) | JP2006510663A (es) |
| KR (1) | KR20050085538A (es) |
| CN (1) | CN1735441A (es) |
| AP (1) | AP2005003336A0 (es) |
| AU (1) | AU2003283656A1 (es) |
| BR (1) | BR0317229A (es) |
| CA (1) | CA2509142A1 (es) |
| CO (1) | CO5700801A2 (es) |
| CR (1) | CR7868A (es) |
| EA (1) | EA200500783A1 (es) |
| EC (1) | ECSP055852A (es) |
| HR (1) | HRP20050522A2 (es) |
| IS (1) | IS7858A (es) |
| MA (1) | MA27606A1 (es) |
| MX (1) | MXPA05006336A (es) |
| NO (1) | NO20053185L (es) |
| OA (1) | OA12969A (es) |
| PL (1) | PL377552A1 (es) |
| TN (1) | TNSN05158A1 (es) |
| WO (1) | WO2004052461A1 (es) |
| ZA (1) | ZA200504338B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| GB0310867D0 (en) * | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
| KR101176670B1 (ko) | 2004-03-25 | 2012-08-23 | 메모리 파마슈티칼스 코포레이션 | 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸, 및그의 제조법 및 용도 |
| GB0424564D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| WO2008083442A1 (en) * | 2007-01-10 | 2008-07-17 | Brc Operations Pty Limited | Method for formulating combination medications for adhd |
| CA2681934A1 (en) * | 2007-03-28 | 2008-10-02 | High Point Pharmaceuticals, Llc | 11beta-hsd1 active compounds |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| MX2010009110A (es) * | 2008-02-19 | 2010-11-30 | Adolor Corp | Beloxepina, sus enantiomeros, y analogos de la misma para el tratamiento de dolor. |
| US8927549B2 (en) | 2008-11-21 | 2015-01-06 | High Point Pharmaceuticals, Llc | Adamantyl benzamide derivatives |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| EP2571874B1 (en) | 2010-05-17 | 2016-03-30 | Forum Pharmaceuticals Inc. | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
| WO2012015715A1 (en) | 2010-07-27 | 2012-02-02 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators |
| AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2023022256A1 (ko) | 2021-08-19 | 2023-02-23 | 단국대학교 천안캠퍼스 산학협력단 | Kds2010을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물 |
| KR20230027862A (ko) | 2021-08-20 | 2023-02-28 | 단국대학교 천안캠퍼스 산학협력단 | 주의력결핍 과잉행동장애의 진단을 위한 gat-3의 용도 |
| KR102597711B1 (ko) | 2021-08-20 | 2023-11-06 | 단국대학교 천안캠퍼스 산학협력단 | Snap5114을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물 |
| WO2023022269A1 (ko) | 2021-08-20 | 2023-02-23 | 단국대학교 천안캠퍼스 산학협력단 | 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020016334A1 (en) * | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
| US20030236287A1 (en) * | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
-
2003
- 2003-11-28 EP EP03775637A patent/EP1572300A1/en not_active Withdrawn
- 2003-11-28 AU AU2003283656A patent/AU2003283656A1/en not_active Abandoned
- 2003-11-28 WO PCT/IB2003/005542 patent/WO2004052461A1/en not_active Application Discontinuation
- 2003-11-28 PL PL377552A patent/PL377552A1/pl not_active Application Discontinuation
- 2003-11-28 OA OA1200500174A patent/OA12969A/en unknown
- 2003-11-28 AP AP2005003336A patent/AP2005003336A0/xx unknown
- 2003-11-28 CN CNA2003801084894A patent/CN1735441A/zh active Pending
- 2003-11-28 EA EA200500783A patent/EA200500783A1/ru unknown
- 2003-11-28 BR BR0317229-5A patent/BR0317229A/pt not_active IP Right Cessation
- 2003-11-28 MX MXPA05006336A patent/MXPA05006336A/es not_active Application Discontinuation
- 2003-11-28 KR KR1020057010591A patent/KR20050085538A/ko not_active Application Discontinuation
- 2003-11-28 JP JP2004558921A patent/JP2006510663A/ja active Pending
- 2003-11-28 CA CA002509142A patent/CA2509142A1/en not_active Abandoned
-
2004
- 2004-10-12 US US10/963,922 patent/US20050107425A1/en not_active Abandoned
-
2005
- 2005-05-23 IS IS7858A patent/IS7858A/is unknown
- 2005-05-27 ZA ZA200504338A patent/ZA200504338B/en unknown
- 2005-06-09 HR HR20050522A patent/HRP20050522A2/hr not_active Application Discontinuation
- 2005-06-10 EC EC2005005852A patent/ECSP055852A/es unknown
- 2005-06-10 TN TNP2005000158A patent/TNSN05158A1/fr unknown
- 2005-06-10 CR CR7868A patent/CR7868A/es not_active Application Discontinuation
- 2005-06-10 MA MA28325A patent/MA27606A1/fr unknown
- 2005-06-10 CO CO05056569A patent/CO5700801A2/es not_active Application Discontinuation
- 2005-06-29 NO NO20053185A patent/NO20053185L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR7868A (es) | 2005-07-08 |
| BR0317229A (pt) | 2005-11-01 |
| KR20050085538A (ko) | 2005-08-29 |
| EA200500783A1 (ru) | 2005-12-29 |
| PL377552A1 (pl) | 2006-02-06 |
| ZA200504338B (en) | 2006-07-26 |
| ECSP055852A (es) | 2005-09-20 |
| EP1572300A1 (en) | 2005-09-14 |
| OA12969A (en) | 2006-10-13 |
| US20050107425A1 (en) | 2005-05-19 |
| WO2004052461A1 (en) | 2004-06-24 |
| AU2003283656A1 (en) | 2004-06-30 |
| CA2509142A1 (en) | 2004-06-24 |
| TNSN05158A1 (fr) | 2007-05-14 |
| MA27606A1 (fr) | 2005-11-01 |
| NO20053185D0 (no) | 2005-06-29 |
| JP2006510663A (ja) | 2006-03-30 |
| CN1735441A (zh) | 2006-02-15 |
| IS7858A (is) | 2005-05-23 |
| AP2005003336A0 (en) | 2005-06-30 |
| NO20053185L (no) | 2005-08-17 |
| MXPA05006336A (es) | 2005-08-26 |
| HRP20050522A2 (en) | 2005-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5700801A2 (es) | Tratamiento del transtorno por deficit de atencion con hiper actividad | |
| ATE536349T1 (de) | In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
| NO20073783L (no) | Pyrrolidininhibitorer for IAP | |
| CO5700765A2 (es) | 2-(piridin-2-ilamino)-pirido[2,3-d] pirimidin-7-onas | |
| CY1105386T1 (el) | Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου | |
| ATE402180T1 (de) | Verbindungen zur behandlung von dyslipidemie | |
| ATE528304T1 (de) | Verbindungen und verfahren zur behandlung von dyslipidämie | |
| ATE459621T1 (de) | Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung | |
| EA200700702A1 (ru) | Аналоги локсапина и способы их применения | |
| ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
| TW200740773A (en) | Diaminopyrimidines as P2X3 and P2X2/3 modulators | |
| NO20043013L (no) | Tetrahydrokinolin analoger som muskarine agonister | |
| ES2258642T3 (es) | Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina. | |
| ATE446753T1 (de) | Verwendung von substituierten 2-thio-3,5-dicyano- 4-phenyl-6-aminopyridinen bei der behandlung von übelkeit und erbrechen | |
| ATE521357T1 (de) | Verfahren zur behandlung von hepatitis | |
| ATE373474T1 (de) | Substituierte 2-aminotetraline zur behandlung von depressionen | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| CO6341610A2 (es) | Compuesto heterociclilo aromatico que contiene nitrogeno. | |
| EA200701866A1 (ru) | Стабилизирующая композиция для галогенидсодержащих полимеров | |
| SV2004001555A (es) | Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos | |
| EA200600440A1 (ru) | 4-((феноксиалкил)тио)еноксиуксусные кислоты и их аналоги | |
| HN2002000110A (es) | Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple. | |
| CO5060426A1 (es) | 1-aril-3-imidiopirazoles plaguicidas | |
| NO20071100L (no) | 5-jodtetrazoler | |
| DE60329326D1 (de) | Tace inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |